Skip to main content
Muscle Disease Research

Muscular Dystrophy Mouse Models

Since 1998, ingenious targeting laboratory has supported muscular dystrophy research with custom mouse models enabling mechanistic studies of muscle degeneration, testing gene therapy approaches, and developing therapeutic interventions for Duchenne muscular dystrophy and related myopathies.

Muscular dystrophy mouse models provide essential platforms for investigating molecular pathways underlying muscle wasting and testing exon skipping strategies and gene replacement therapies.

2,500+
Projects Completed
800+
Publications
26+
Years Experience
100%
Success Rate

Duchenne Muscular Dystrophy Models

mdx Mouse

Point mutation in exon 23 creating premature stop codon. Complete absence of full length dystrophin. Standard model for preclinical studies.

  • Milder than human DMD due to compensatory utrophin
  • Elevated CK and muscle regeneration
  • Widely used for baseline studies

mdx/utrophin Double Knockout

Elimination of both dystrophin and utrophin produces severe muscular dystrophy with shortened lifespan, closely modeling human DMD severity.

  • Severe phenotype matching human disease
  • Shortened lifespan
  • Optimal for therapeutic testing

Humanized DMD Models

hDMDTg mice carrying full length human DMD gene enable testing of human specific therapies including exon skipping oligonucleotides.

  • Human sequence for ASO testing
  • Exon skipping validation
  • Clinical translation studies

Phenotyping Muscular Dystrophy Models

Functional Assessment

  • Grip strength (forelimb/hindlimb)
  • Rotarod (motor coordination)
  • Treadmill endurance
  • Voluntary wheel running

Pathological Assessment

  • H&E staining (centralized nuclei, necrosis)
  • Fibrosis (Sirius red/trichrome)
  • IHC for dystrophin complex

Biomarkers Assessment

  • Serum creatine kinase (CK)
  • Cardiac troponin
  • Myoglobin

Cardiac Assessment

  • Echocardiography
  • ECG
  • Hemodynamics

Therapeutic Applications

Gene Therapy

  • AAV microdystrophin delivery
  • Utrophin upregulation
  • Dual/triple vector strategies

Exon Skipping

  • Antisense oligonucleotides
  • Eteplirsen class drugs
  • Human sequence specific ASOs

Cell Based

  • Satellite cell transplantation
  • iPSC derived myocytes
  • Patient specific approaches

What Researchers Say

iTL produced a new conditional mouse model for us and the quality of service was exceptional. The team is extremely knowledgeable and the work was completed at the highest possible standards. My project manager was excellent and always happy to answer technical questions and keep me up to date with progress and potential problems. I would recommend iTL highly and will use them again in the future if I need to generate a new mouse line.

Albert Basson, PhD

King's College London

✦ New for 2026

Breeding Scheme Architect

Plan complex multi-allele breeding strategies, calculate expected genotype ratios, and estimate time to experimental cohorts—all before starting your project.

Visualize multi-generation breeding paths
Calculate Mendelian ratios automatically
Estimate timeline to study ready cohorts

Free Research Tool

No account required

Allele 1Gene-flox (conditional)
Allele 2Cre-driver (tissue-specific)
TargetHomozygous knockout

→ 3 generations to target genotype

Start Your Muscular Dystrophy Model Project

Our scientific consultants can help design custom muscular dystrophy models tailored to your research questions, whether studying disease mechanisms or testing therapeutic approaches.

Frequently asked questions

Models include mdx (Duchenne muscular dystrophy with dystrophin mutation), knockout models of dystrophin associated proteins, point mutation knockins modeling specific patient variants, and conditional models for tissue specific studies. Models can be combined with gene therapy testing approaches.

Phenotyping includes functional assessment (grip strength, rotarod, treadmill endurance), muscle pathology (H&E staining, fibrosis assessment, immunohistochemistry), serum biomarkers (creatine kinase, myoglobin), and cardiac assessment (echocardiography, ECG, hemodynamics).

Yes. Muscular dystrophy models are extensively used for testing gene therapy approaches including AAV mediated dystrophin delivery, exon skipping strategies, and CRISPR based correction. Models enable evaluation of therapeutic efficacy, safety, and long term persistence.

Common muscle Cre drivers include MCK Cre and HSA Cre for skeletal muscle, alphaMHC Cre for cardiac muscle, and MyoD Cre for muscle progenitors. Tamoxifen inducible Cre (CreER) enables temporal control for adult onset studies.

Lab Signals

Stay Updated on Muscular Dystrophy Research

Get the latest insights on DMD models, gene therapy approaches, and muscle disease therapeutics.

Subscribe Free

Related resources